Enhanced quadrivalent influenza vaccine against seasonal influenza for the 2023/2024 influenza season

Folkehelseinstituttet

The Norwegian Institute of Public Health (FHI) is inviting tenderers to an open tender for an Enhanced quadrivalent influenza vaccine against seasonal influenza for vaccination of particularly vulnerable persons from 65 years and older (nursing home residents, users of home nursing care, etc.) An enhanced quadrivalent influenza vaccine is a vaccine that is more effective than the ordinary influenza vaccine that is offered to other target groups in the national vaccination programme.
The aim is to enter into a contract for the delivery of 80,000 doses of enhanced quadrivalent influenza vaccine. It is important that the enhanced quadrivalent influenza vaccine can be delivered in time for FHI to distribute vaccine doses to end users in all of Norway's municipalities, before the flu season starts.

Frist

Fristen for mottak av tilbud var 2023-01-04. Anskaffelsen ble publisert 2022-11-25.

Leverandører

Følgende leverandører er nevnt i tildelingsbeslutninger eller andre anskaffelsesdokumenter:

Hvem? Hva? Hvor?
Anskaffelseshistorikk
Dato Dokument
2022-11-25 Kunngjøring av konkurranse
2023-03-31 Kunngjøring om tildeling av kontrakt
Kunngjøring av konkurranse (2022-11-25)
Gjenstand
Anskaffelsens omfang
Tittel: Influenza vaccines
Referansenummer: 22/03656
Kort beskrivelse:
The Norwegian Institute of Public Health (FHI) is inviting tenderers to an open tender for an Enhanced quadrivalent influenza vaccine against seasonal influenza for vaccination of particularly vulnerable persons from 65 years and older (nursing home residents, users of home nursing care, etc.) An enhanced quadrivalent influenza vaccine is a vaccine that is more effective than the ordinary influenza vaccine that is offered to other target groups in the national vaccination programme. The aim is to enter into a contract for the delivery of 80,000 doses of enhanced quadrivalent influenza vaccine. It is important that the enhanced quadrivalent influenza vaccine can be delivered in time for FHI to distribute vaccine doses to end users in all of Norway's municipalities, before the flu season starts.
Vis mer
Metadata for kunngjøring
Originalspråk: engelsk 🗣️
Dokumenttype: Kunngjøring av konkurranse
Kontraktens art: Varer
Forskrift: Det europeiske økonomiske samarbeidsområdet (EØS), med deltakelse av GPA-land
Felles innkjøpsordliste (CPV)
Kode: Influensavaksine 📦
Tilleggs-CPV: Vaksiner 📦
Utførelsessted
NUTS-region: Norge 🏙️

Prosedyre
Prosedyretype: Åpen anbudskonkurranse
Tilbudstype: Innlevering for alle delkontrakter
Tildelingskriterier
Det mest økonomisk fordelaktige tilbudet

Oppdragsgiver
Identitet
Land: Norge 🇳🇴
Type tildelende myndighet: Departement eller annen nasjonal eller føderal myndighet
Navn på tildelende myndighet: Folkehelseinstituttet
Postadresse: Lovisenberggata 8
Postnummer: 0456
Poststed: Oslo
Kontakt
Internettadresse: http://www.fhi.no 🌏
E-post: ole.andreas.fuglesang@fhi.no 📧
Telefon: +47 21076629 📞
URL for dokumenter: http://eu.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=347067&B=DFO 🌏
URL for deltakelse: http://eu.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=347067&B=DFO 🌏

Referanse
Datoer
Sendt dato: 2022-11-25 📅
Innleveringsfrist: 2023-01-04 📅
Publiseringsdato: 2022-11-30 📅
Identifikatorer
Kunngjøringsnummer: 2022/S 231-666883
OJ-S-utgave: 231
Tilleggsinformasjon
Specification of section II.2.7 'The duration of the contract, the framework agreement or the dynamic purchasing systems. The Norwegian Institute of Public Health (FHI) emphasises that the contract period is determined in accordance with the Supply Agreement, chapter 17 with sub-points.
Vis mer

Gjenstand
Anskaffelsens omfang
Kort beskrivelse:
The Norwegian Institute of Public Health (FHI) is inviting tenderers to an open tender for an Enhanced quadrivalent influenza vaccine against seasonal influenza for vaccination of particularly vulnerable persons from 65 years and older (nursing home residents, users of home nursing care, etc.) An enhanced quadrivalent influenza vaccine is a vaccine that is more effective than the ordinary influenza vaccine that is offered to other target groups in the national vaccination programme.
Vis mer
The aim is to enter into a contract for the delivery of 80,000 doses of enhanced quadrivalent influenza vaccine. It is important that the enhanced quadrivalent influenza vaccine can be delivered in time for FHI to distribute vaccine doses to end users in all of Norway's municipalities, before the flu season starts.
Vis mer
Estimert totalverdi: 26 000 000 NOK 💰
Estimert verdi eksklusive mva: 26 000 000 NOK 💰
Varighet: 12 måneder
Tilleggsinformasjon:
Specification of section II.2.7 'The duration of the contract, the framework agreement or the dynamic purchasing systems. The Norwegian Institute of Public Health (FHI) emphasises that the contract period is determined in accordance with the Supply Agreement, chapter 17 with sub-points.
Vis mer
Utførelsessted
Hovedsted eller utførelsessted: Oslo, Norway.

Juridisk, økonomisk, finansiell og teknisk informasjon
Vilkår for deltakelse
Egnethet til å utøve yrkesvirksomheten:
REQUIREMENT:
Tenderers must be registered in a company register, professional register or a trade register in the country where the tenderer is established.
Documentation requirement:
Norwegian companies: Company registration certificate
Foreign tenderers: Verification showing that the tenderer is registered in a company register, professional register or a commerce register in the country where the tenderer is established.
Teknisk og faglig kapasitet:
REQUIREMENT:
The tenderer must have the requisite permissions to be able to fulfil the contract.
Documentation requirement:
If the tenderer is the manufacturer of the vaccine, permission must be presented from relevant EU/EEA authorities to manufacture pharmaceuticals.
If the tenderer is not the manufacturer of the vaccine, the requisite permissions from relevant EU/EEA authorities to trade in pharmaceuticals must be presented.
If the tenderer imports the vaccine, the import license that includes the offered vaccine must be presented.

Prosedyre
Rettslig grunnlag: 32014L0024
Tidspunkt for mottak av tilbud: 13:00
Språk som tilbud eller forespørsler om deltakelse kan sendes inn på: engelsk 🗣️
norsk 🗣️
Tilbudets gyldighetsperiode: 2023-03-30 📅
Dato for åpning av tilbud: 2023-01-04 📅
Tidspunkt for åpning av tilbud: 13:00
Sted: The opening of tenders are carried out electronically in the contracting authority's electronic tender management and implementation system (Norwegian: KGV). Two employees from the Norwegian Institute of Public Health (FHI) with a user licence in the tender management and implementation system will carry out the opening of tenders.
Tilleggsinformasjon: See the above.
Tildelingskriterier
Kvalitetskriterium (navn): Delivery
Kvalitetskriterium (vekting): 30%
Pris (vekting): 70%

Oppdragsgiver
Identitet
Nasjonalt registreringsnummer: 983 744 516
Kontakt
Kontaktpunkt: Ole Andreas Fuglesang
Adresse til kjøperprofilen: https://eu.eu-supply.com/ctm/Company/CompanyInformation/Index/346372 🌏
URL for dokumenter: http://eu.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=347067&B=DFO 🌏

Referanse
Tilleggsinformasjon
Estimert tidsplan for ytterligere kunngjøringer: Autumn 2023

Utfyllende informasjon
Klageinstans
Navn: Oslo tingrett
Postadresse: Postboks 2106 Vika
Poststed: Oslo
Postnummer: 0125
Land: Norge 🇳🇴
Telefon: +47 22035200 📞
E-post: oslo.tingrett@domstol.no 📧
Internettadresse: https://www.domstol.no/Enkelt-domstol/oslotingrett/ 🌏
Kilde: OJS 2022/S 231-666883 (2022-11-25)
Kunngjøring om tildeling av kontrakt (2023-03-31)
Gjenstand
Anskaffelsens omfang
Kort beskrivelse:
The Norwegian Institute of Public Health (FHI) has carried out an open tender for an Enhanced quadrivalent influenza vaccine against seasonal influenza for vaccination of particularly vulnerable persons from 65 years and older (nursing home residents, users of home nursing care, etc.) An enhanced quadrivalent influenza vaccine is a vaccine that is more effective than the ordinary influenza vaccine that is offered to other target groups in the national vaccination programme. The aim was to enter into a contract for the delivery of 80,000 doses of enhanced quadrivalent influenza vaccine. It is important that the enhanced quadrivalent influenza vaccine can be delivered in time for FHI to distribute vaccine doses to end users in all of Norway's municipalities, before the flu season starts.
Vis mer
Totalverdi for anskaffelsen: 26 000 000 NOK 💰
Metadata for kunngjøring
Dokumenttype: Kunngjøring om tildeling av kontrakt

Prosedyre
Tilbudstype: Ikke aktuelt

Referanse
Datoer
Sendt dato: 2023-03-31 📅
Publiseringsdato: 2023-04-05 📅
Identifikatorer
Kunngjøringsnummer: 2023/S 068-203009
Refererer til kunngjøring: 2022/S 231-666883
OJ-S-utgave: 68
Tilleggsinformasjon
The actual contract value is kept from public access and is therefore not given in the notice. C.f. section V.2.4) Price per dose (unit price) is the only price element in the contest. FHI considers unit prices to be information of competitive importance to keep secret from whom the information relates, who in this case is Seqirus. The information is therefore subject to client confidentiality. If the actual contract value had been stated in the tender notice, it would have been feasible to calculate the unit price using publicly available information on the number of doses. The actual contract value is kept from public access and is therefore not given in the notice. C.f. the Public Act §13 and the Public Administration Act §13 first paragraph, point 2. FHI informs that the contract value is higher than the highest threshold value in the public procurement regulations and lower than the procurement's pre-estimated total value ref. section II.1.7)
Vis mer

Gjenstand
Anskaffelsens omfang
Kort beskrivelse:
The Norwegian Institute of Public Health (FHI) has carried out an open tender for an Enhanced quadrivalent influenza vaccine against seasonal influenza for vaccination of particularly vulnerable persons from 65 years and older (nursing home residents, users of home nursing care, etc.) An enhanced quadrivalent influenza vaccine is a vaccine that is more effective than the ordinary influenza vaccine that is offered to other target groups in the national vaccination programme.
Vis mer
The aim was to enter into a contract for the delivery of 80,000 doses of enhanced quadrivalent influenza vaccine. It is important that the enhanced quadrivalent influenza vaccine can be delivered in time for FHI to distribute vaccine doses to end users in all of Norway's municipalities, before the flu season starts.
Vis mer

Tildeling av kontrakt
Dato for kontraktinngåelse: 2023-03-23 📅
Navn: Seqirus UK Limited
Nasjonalt registreringsnummer: N/a
Postadresse: 29 Market St
Poststed: Maidenhead
Postnummer: SL6 8AA
Land: Storbritannia 🇬🇧
Telefon: +441 628641500 📞
E-post: ramon.guitart@seqirus.com 📧
Totalverdi for anskaffelsen: 1 NOK 💰
Informasjon om tilbud
Antall mottatte tilbud: 2

Referanse
Tilleggsinformasjon
The actual contract value is kept from public access and is therefore not given in the notice. C.f. section V.2.4)
Price per dose (unit price) is the only price element in the contest. FHI considers unit prices to be information of competitive importance to keep secret from whom the information relates, who in this case is Seqirus. The information is therefore subject to client confidentiality. If the actual contract value had been stated in the tender notice, it would have been feasible to calculate the unit price using publicly available information on the number of doses. The actual contract value is kept from public access and is therefore not given in the notice. C.f. the Public Act §13 and the Public Administration Act §13 first paragraph, point 2.
Vis mer
FHI informs that the contract value is higher than the highest threshold value in the public procurement regulations and lower than the procurement's pre-estimated total value ref. section II.1.7)
Kilde: OJS 2023/S 068-203009 (2023-03-31)
Nye anskaffelser i relaterte kategorier 🆕
Relaterte søk 🔍
Produkter/tjenester:
Medisinsk utstyr, legemidler og utstyr... Farmasøytiske produkter Antiinfektive midler for systemisk bruk,... Antiinfektive midler for systemisk bruk Vaksiner Influensavaksine